News Agency
Men's Weekly

KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE

  • Written by PR Newswire
KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE

SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298).

The data is the subject of a poster presentation at the Annual Meeting...

Read more: KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED...

Managing Business Risk Through Content Governance in Headless CMS

As businesses scale their digital presence, content becomes a critical asset that directly impacts reputation, compliance, and operational efficiency. However, without proper governance, content can quickly become a source of risk. Inaccurate information, inconsistent messaging, or non-compliant content can lead... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion